I sent the following email to JDN. If there are any specific points anyone would have liked emphasized, let me know and I can send a followup message.I have never talked to Susan Lorigan, Sunrise's investor relations person. I hope she is a good contact number to have offered. Some IR people are very informed and helpful, I've found, and others are basically receptionists who will send you a packet if you insist.
Dear JDN:
This is to suggest for The Team's consideration, Sunrise Technologies (SNRS).
Their website contains descriptions of their opthalmic treatment systems, recent press releases, Wall Street coverage information (Red Chip and Penn.Merchant), etc. It is:
sunrise-tech.com
Their investor relations person is Susan Lorigan, 510/623-9001
There is a Sunrise Technologies thread on SI:
Subject 8695
The Sunrise thread participants are counting days in hopeful expectation of Nasdaq qualification in the not too distant future (and of course eventual marginability.)
One SNRS shareholder who went to Boca Ratan to observe the procedure (and has been buying heavily), "Nanny," has posted a number of informative (and exhuberant) messages. She describes the constituency for this technology and how the technology differs from that of its "competitors." I don't think it's a stretch to compare Sunrise to TAVA in this regard. TAVA is the only game in town for embeds, SNRS will be the treatment of choice for the farsighted, aka "hyperopes," and for treatment of the overcorrected myopic patients of VISX or BEAM . You can get more detail about the procedure and its costs, benefits, etc. from the above website and from investor relations, and the following links to posts by Nanny on the SI SNRS thread make for some good initial reading.
Message 2576202
Message 2580335
Message 2632593
Message 2648768
|
